Evidence map›Paper›PMID 40920871›Full record

ArticleBlood2025

Platelet factor 4 regulates hematopoietic stem cell aging.

Sen Zhang, Charles E Ayemoba, Anna M Di Staulo, Kenneth Joves, Chandani M Patel, Eva Hin Wa Leung, Maura Lima Pereira Bueno, Xiaoping Du, Mortimer Poncz, Sang-Ging Ong and 4 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Improving lymphopoiesis in aged bone marrow.Current opinion in hematology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sen ZhangDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0003-3849-6817
Charles E AyemobaDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-1191-6159
Anna M Di StauloDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-0188-4149
Kenneth JovesDepartment of Biochemistry and Molecular Genetics, University of Illinois Chicago, Chicago, IL.
Chandani M PatelDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0009-0000-7240-7190
Eva Hin Wa LeungDepartment of Biochemistry and Molecular Genetics, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-5744-5882
Maura Lima Pereira BuenoDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0003-2979-5145
Xiaoping DuDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0001-9842-8192
Mortimer PonczDepartment of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
Sang-Ging OngDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0003-0182-8769
Claus NerlovMedical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Maria MaryanovichThe Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY.ORCID 0000-0002-2015-0538
Constantinos ChronisDepartment of Biochemistry and Molecular Genetics, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-7783-8202
Sandra PinhoDepartment of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL.ORCID 0000-0002-5241-7364

Funding

TRAINING PROGRAM IN LUNG BIOLOGY AND PATHOBIOLOGYT32HL007829 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOLLY MEHTA · 1995 to 2026
$15.6M
New Mechanistic Insights & Therapeutic Applications of Megakaryocytes/PlateletsR35HL150698 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Mortimer Poncz · 2020 to 2026
$7.3M
Mechanisms of integrin signaling and a new anti-platelet/anti-inflammatory approachR35HL150797 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Xiaoping Du · 2020 to 2026
$6.8M
Training Core for Chicago KUH FORWARDTL1DK132769 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Tamara Isakova · 2021 to 2026
$4.0M
Mechanisms of hematopoietic stem cell engraftmentR01HL162584 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Sandra Pinho · 2022 to 2026
$2.2M
Reprogramming Gene Regulatory Networks to a Hematopoietic Stem Cell StateR01HL170286 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Konstantinos Chronis · 2023 to 2026
$2.1M
Regulation of hematopoietic stem cell niche aging by the sympathetic nervous systemR01HL174801 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Maria Marianovich · 2024 to 2026
$1.7M
Molecular mechanisms of translational control in sunitinib-induced vascular dysfunctionR01HL173315 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Sang Ging Ong · 2025 to 2026
$1.4M
REGULATION OF BONE MARROW MESENCHYMAL STEM CELLS BY VCAM1F31HL165859 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DI STAULO, ANNA MARISA · 2022 to 2025
$114k
NHLBI NIH HHS F31 HL165859NHLBI NIH HHS R01 HL162584NHLBI NIH HHS R01 HL170286NHLBI NIH HHS R01 HL173315NHLBI NIH HHS R01 HL174801NHLBI NIH HHS R35 HL150698NHLBI NIH HHS R35 HL150797NHLBI NIH HHS T32 HL007829NIDDK NIH HHS TL1 DK132769
6 · The paper itself

Abstract

abstractHematopoietic stem cells (HSCs) responsible for blood cell production and their bone marrow regulatory niches undergo age-related changes, affecting immune responses and predisposing individuals to hematologic malignancies. Here, we show that the age-related alterations of the megakaryocytic niche and associated downregulation of platelet factor 4 (PF4) are pivotal mechanisms driving HSC aging. PF4-deficient mice display several phenotypes reminiscent of accelerated HSC aging, including lymphopenia, increased myeloid output, and DNA damage, mimicking physiologically aged HSCs. Remarkably, recombinant PF4 administration restored old HSCs to youthful functional phenotypes characterized by improved cell polarity, reduced DNA damage, enhanced in vivo reconstitution capacity, and balanced lineage output. Mechanistically, we identified low-density lipoprotein receptor and C-X-C motif chemokine receptor 3 as HSC receptors transmitting the PF4 signal, with double knockout mice exhibiting exacerbated HSC aging phenotypes similar to PF4-deficient mice. Furthermore, human HSCs across various age groups also respond to the youthful PF4 signaling, highlighting its potential for rejuvenating aged hematopoietic systems. These findings pave the way for targeted therapies aimed at reversing age-related HSC decline, with potential implications in the prevention or improvement of the course of age-related hematopoietic diseases.

Indexed as

Cellular SenescenceHematopoietic Stem CellsPlatelet Factor 4AgingAnimalsHumansMiceMice, Inbred C57BLMice, KnockoutSignal TransductionPlatelet Factor 4

Identifiers

PMID40920871
PMCPMC12574973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.